Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity

A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of non-immunogenic tumors to allow T cell-mediated anticancer activity

(2019) Hayley S. Ma et al.   Cancer Immunology Research

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

(2019) Tuba N. Gide et al.   CANCER CELL

Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)

(2019) Nune Markosyan et al.   JOURNAL OF CLINICAL INVESTIGATION

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

CD40 Agonist Antibodies in Cancer Immunotherapy

(2019) Robert H. Vonderheide   Annual Review of Medicine

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

(2019) Spencer C. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer

(2018) Andrew J Rech et al.   CANCER RESEARCH

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy

(2018) Jinyang Li et al.   IMMUNITY

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

(2018) Carsten Krieg et al.   NATURE MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

TLR Stimulation During T-cell Activation Lowers PD-1 Expression on CD8+ T Cells

(2018) Christopher D. Zahm et al.   Cancer Immunology Research

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

(2018) David L. Bajor et al.   OncoImmunology

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

(2017) Enfu Hui et al.   SCIENCE

Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity

(2017) Casey R. Ager et al.   Cancer Immunology Research

Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8 + T Cells

(2017) Christopher D. Zahm et al.   Cancer Immunology Research

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor

(2016) Shin Foong Ngiow et al.   CANCER RESEARCH

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1

(2016) Peng Yin et al.   Oncotarget

CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer

(2016) Katelyn T. Byrne et al.   Cell Reports

Innate Immune Recognition of Cancer

(2015) Seng-Ryong Woo et al.   Annual Review of Immunology

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells

(2015) A. Lo et al.   CANCER RESEARCH

Diverse Roles for T-bet in the Effector Responses Required for Resistance to Infection

(2015) Gretchen Harms Pritchard et al.   JOURNAL OF IMMUNOLOGY

Flt3 Ligand Is Essential for Survival and Protective Immune Responses during Toxoplasmosis

(2015) Christopher D. Dupont et al.   JOURNAL OF IMMUNOLOGY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment

(2015) A. Zippelius et al.   Cancer Immunology Research

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

(2015) R. Winograd et al.   Cancer Immunology Research

Radiation as Immunomodulator: Implications for Dendritic Cell-Based Immunotherapy

(2014) Robert E. Roses et al.   RADIATION RESEARCH

Parasite Fate and Involvement of Infected Cells in the Induction of CD4+ and CD8+ T Cell Responses to Toxoplasma gondii

(2014) Christopher D. Dupont et al.   PLoS Pathogens

Agonistic CD40 Antibodies and Cancer Therapy

(2013) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies

(2012) M J McCoy et al.   BRITISH JOURNAL OF CANCER

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Vera Hirsh et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed Death 1 Regulates Development of Central Memory CD8 T Cells after Acute Viral Infection

(2011) S. R. Allie et al.   JOURNAL OF IMMUNOLOGY

MPYS Is Required for IFN Response Factor 3 Activation and Type I IFN Production in the Response of Cultured Phagocytes to Bacterial Second Messengers Cyclic-di-AMP and Cyclic-di-GMP

(2011) L. Jin et al.   JOURNAL OF IMMUNOLOGY

Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study

(2011) A. Carpentier et al.   NEURO-ONCOLOGY

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma

(2009) Jeffrey S. Weber et al.   CANCER

Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects

(2009) H.-I. Cho et al.   CANCER RESEARCH

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation

(2009) Erica L Carpenter et al.   Journal of Translational Medicine

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines

(2008) C. L. Ahonen et al.   BLOOD

Toll-like Receptors Activate Innate and Adaptive Immunity by using Dendritic Cell-Intrinsic and -Extrinsic Mechanisms

(2008) Baidong Hou et al.   IMMUNITY

Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod

(2008) Manon van Seters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

(2008) K. Hildner et al.   SCIENCE